Published in the Lancet Psychiatry, the research also examined data on new diagnoses of anxiety and depression
Interaction with the glucagon receptor is an important part of how retatrutide helps with weight loss
Fat loss continues while lean mass stabilizes (if protein intake adequate and resistance training implemented)
Access and coverage are key hurdles
Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isnt serious enough for treatment, said David A Ricks, chair and CEO of Eli Lilly, in a statement
There is no consistent, reproducible body of evidence [supporting increased suicidal ideation]